---
id: ags-polypharmacy-2024
title: "AGS 2024 Expert Panel Consensus: Polypharmacy and Deprescribing in Older Adults"
short_title: "AGS Polypharmacy 2024"

organization: American Geriatrics Society
collaborators: null
country: US
url: https://www.americangeriatrics.org/
doi: null
pmid: null
open_access: true

specialty: geriatrics
guideline_type: clinical-practice
evidence_system: AGS Expert Panel
conditions:
  - polypharmacy
  - deprescribing
  - medication management
tags:
  - Beers criteria
  - medication review
  - drug interactions
  - falls
  - anticholinergic burden

publication_date: 2024-03-01
previous_version_date: null
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 AGS expert consensus on addressing polypharmacy and implementing deprescribing strategies in older adults.

## Key Recommendations

### Definition
- **Polypharmacy**: Use of â‰¥5 medications. Often associated with increased risk of adverse drug events, drug-drug interactions, falls, cognitive impairment, and non-adherence.

### When to Conduct Medication Review
- At transitions of care (hospital discharge, new admission to long-term care).
- After a fall, hospitalization, or new diagnosis.
- When adding a new medication ("prescribing cascade" check).
- Periodically (at least annually) for all older adults on multiple medications.

### Deprescribing Approach
1. **Ascertain all medications**: Include OTC, supplements, herbals.
2. **Assess each medication**: Is there still an indication? Is the benefit > harm for this patient?
3. **Prioritize for deprescribing**: Target medications with high harm potential (Beers Criteria, STOPP/START), those without clear indication, or those contributing to a drug cascade.
4. **Implement gradual withdrawal**: Taper when appropriate (e.g., PPIs, benzodiazepines, antidepressants).
5. **Monitor and support**: Watch for withdrawal symptoms or return of the original condition.

### High-Priority Targets for Deprescribing
- Proton pump inhibitors (long-term use without indication).
- Benzodiazepines and Z-drugs.
- Opioids.
- Anticholinergic medications.
- High-risk diabetes medications (long-acting sulfonylureas).
- Antipsychotics in dementia (unless for severe agitation without alternatives).

### Shared Decision-Making
- Engage the patient and family/caregivers. Discuss goals of care, life expectancy, and priorities.
